Progression of the FLT3 Inhibitor in acute myeloid leukemia
10.3760/cma.j.issn.1009-9921.2009.02.021
- VernacularTitle:FLT3抑制剂在急性髓细胞白血病中的研究进展
- Author:
Jiazhuo LIU
;
Jianxiang WANG
- Publication Type:Journal Article
- Keywords:
Receptor protein-tyrosine kinases;
Mutation;
Inhibins;
Leukemia,myelocytic,acute
- From:
Journal of Leukemia & Lymphoma
2009;18(2):120-123
- CountryChina
- Language:Chinese
-
Abstract:
FLT3, a tyrosine kinase receptor, is the most common mutation in AML and has two classes of mutations: internal tandem duplications in the juxtamembrane domain (FLT3-ITDs) and point mutations in the tyrosine kinase domain (FLT3-TKDs). AML patients with FLT3 mutations tend to have a poor prognosis. As an independent factor, the presences of FLT3 mutations play an important role in the origin and development of AML and have prognostic value. Molecular targeted therapy represents a novel and popular therapeutic approach in the world. In this review, we explain clinical value of the FLT3 mutations, mechanism and research progression of the FLT3 inhibitor;and discuss difficulties and perspectives in the research of the FLT3 inhibitor.
